SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Declines By 29.2%

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 28,385...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) to Issue Quarterly Dividend of $0.13

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, December 23rd. Shareholders of record on Wednesday, December 24th will be paid a dividend of 0.1346 per...

<ul class="summary-bullets"><li>With Abivax now trading as a strategic asset rather than a pure clinical story, takeover interest from a deep-pocketed pharma player introduces a potential valuation floor.</li><li>At roughly an $11 billion market cap, the stock is priced with strong odds of UC success and meaningful commercialization.</li><li>There is still room for upside if Crohn’s disease data validate a broader, multi-indication franchise.</li></ul>French clinical-stage biotech Abivax (ABVX) had an uneventful Nasdaq debut in October 2023 and spent much of its early public life flying under the radar. That changed abruptly this year after a single clinical data readout flipped the narrative — a familiar inflection point in biotech investing.&nbsp;<a href="https://stocktwits.com/symbol/ABVX">Abivax’s stock</a> is up nearly 1,900% year-to-date, making it the best-performing biotech stock&nbsp;on U.S. exchanges.Adding fuel to the mid-year momentum, Eli Lilly (LLY) has emerged as a potential suitor, with market chatter suggesting the pharma giant is circling the smaller biotech. French media outlet La Lettre reported earlier this week that a delegation of Lilly executives met with the French Treasury and&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.lalettre.fr/fr/entreprises_sante/2025/12/22/l-americain-eli-lilly-en-operation-seduction-a-bercy-pour-racheter-la-biotech-abivax,110583257-art">submitted</a> an acquisition proposal for Abivax.How does this shift the investment thesis around this smaller name? What was once a high-beta, data-driven clinical bet increasingly looks like a strategic M&amp;A optionality trade, with a potential floor under the stock—at least in the near term.<img src="https://news.stocktwits-cdn.com/Abivax_since_IPO_png_b0a5af2a71.webp" alt="Abivax since IPO.png">Source: Koyfin<h2 class="st-heading-2">From Clinical Breakout to Strategic Asset</h2>For all the hype around the name, Abivax is still&nbsp;more or less a one-trick pony. Its lone pipeline asset and lead candidate, Obefazimod, is an immunomodulator that is being evaluated for multiple indications. The indication that is&nbsp;most developed is moderately to severely active ulcerative colitis (UC).&nbsp;Obefazimod acts by enhancing the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. Inflammatory Bowel Disease (IBD), a broader term used to refer to chronic conditions such as UC and Crohn’s disease, is an autoimmune response. The immune system mistakenly attacks the gut, causing inflammation and damage to the digestive tract, leading to symptoms such as diarrhea, abdominal pain, weight loss and fatigue.&nbsp;UC affects the large intestine and rectum, causing ulcers on the inner lining, and Crohn’s disease can affect any part of the gastrointestinal tract and inflames the entire bowel wall.&nbsp;Is the condition such a big opportunity? By Abivax’s own account, it seems so. In a corporate presentation, the company said, citing Evaluate data, that IBD prevalence was 3.6 million in the G7 nations in 2024, with roughly 64% in the U.S. The prevalence is expected to grow at a modest 4% pace over the next six years. Worldwide IBD drug sales in 2024 are estimated at $23.7 billion, with 70% from the U.S.<h4 class="st-heading-4" style="text-align:center;">Worldwide IBD Sales&nbsp;</h4><figure class="image"><img style="aspect-ratio:661/535;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_1_48_03_AM_png_2f93920926.webp" alt="Screenshot 2025-12-24 at 1.48.03 AM.png" width="661" height="535"></figure>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; Source: AbivaxThe current treatment options include:-Interleukin-23 selective inhibitors (block the action of pro-inflammatory cytokine protein interleukin-23)-Sphingosine 1-phosphate (S1P) modulators such as ozanimod and etrasimod (target proteins linked to inflammation on immune cells and stop them from leaving the lymph nodes)-Janus Kinase (JAK) inhibitors (stop several types of pro-inflammatory cytokines from forming)Abivax projects Obefazimod as a differentiated treatment option compared to existing therapies, by enhancing the expression of microRNA-124, a natural regulator of the inflammatory response. The mode of administration is also convenient: an oral once-daily pill with a favorable long-term safety profile.<h2 class="st-heading-2">Wall Street Analysts’ Optimism Abounds</h2>Following topline data from two Phase 3 studies showing the candidate met the primary and secondary endpoints, Abivax stock received love from several Wall Street firms, with Morgan Stanley upgrading the stock to an ‘Overweight,’ according to the Fly.&nbsp;The pooled placebo-adjusted clinical remission for the 50mg dose of 16.4% came in above the roughly 15% bar that Morgan Stanley analysts estimated based on their conversations with investors and experts. The analyst also expected improved odds of success across UC and Crohn's.&nbsp; Guggenheim analysts estimated Obefazimod’s value at $7 billion to $10 billion.Piper Sandler analysts said following the Phase 3 data, they have layered in revenue in early-line UC. This doubles its U.S. UC estimate to 2.66 billion euros ($3.14 billion) in 2035, suggesting there could be significant upside to the stock ahead of key data events.Abivax presented the results of the two late-stage studies at the United European Gastroenterology (UEG) Meeting in Berlin in early October. Citizen JMP analysts, who upped their price target ahead of the event, said the data reinforce Obefazimod’s efficacy and increase conviction in its multi-billion-dollar sales potential. Guggenheim named Abivax as a “Best Idea” and upped its price target to $150.&nbsp;Last month, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $176 price target. The firm based its optimistic assessment on its belief that the company’s odds of success in Crohn’s disease may be higher than those of UC. Crohn’s readout would be a better catalyst in 2026, it added.According to Koyfin, the average analyst price target for Abivax stock is $138.35, implying a 22% downside from current levels. Of the five analysts covering the stock, four have either a ‘Buy’ or a ‘Strong Buy’ rating, and one remains on the sidelines.<h2 class="st-heading-2">Retail Jump Onto Bullish Bandwagon</h2>The Abivax stock stream on Stocktwits has attracted a large following, with the watcher count jumping over 5,500% in the past year. The 30-day message volume is up 2,100%.&nbsp;Retail sentiment toward the stock was ‘extremely bullish’ as of early Wednesday, and it has mainly remained upbeat throughout the year. A bullish&nbsp;<a href="https://stocktwits.com/jeremy0916/message/639921688">watcher</a> has already set his sights on the $230 level for a stock that ended Tuesday’s session at $138.35.<figure class="image"><img style="aspect-ratio:724/433;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_at_3_01_43_AM_png_3c8d4a0547.webp" alt="Screenshot 2025-12-24 at 3.01.43 AM.png" width="724" height="433"></figure><h2 class="st-heading-2">Key Catalysts Investors Are Watching</h2>Fresh off its addition to the Nasdaq Biotechnology Index, Abivax is entering a catalyst-rich phase. The topline results from an ongoing 44-week maintenance trial, dubbed ABTECT-107, are expected to be read out in the second quarter of 2026. The company also plans to release topline data from the Phase 2 Crohn’s Disease study in the second half of next year.<h2 class="st-heading-2">Why Lilly Might Be Interested</h2>Obefazumod could be a better fit in Lilly’s immunology franchise, which includes Omvoh, an IL-23 inhibitor, used as a second-line treatment for adults with moderately to severely active UC and Crohn’s disease. It is administered as an IV infusion. Lilly also acquired Morphic Pharma, thereby adding an oral integrin blocker for UC.Abivax’s current market valuation is roughly $11 billion. The company’s cash position as of Sept. 2025 is 589.7 million euros, and the company said it has a cash runway into the fourth quarter of 2027.&nbsp;Whether that Lilly deal materializes or not, Abivax enters 2026 with elevated expectations, higher stakes, and far more eyes on the name than ever before.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-s-worst-year-in-four-decades-may-end-thanks-to-a-weight-loss-pill/cLepFr2REuw">Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill</a>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen.

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Equity

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.


ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Shares Cross Above 50 Day Moving Average - Here's Why

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Pass Above 50 Day Moving Average - What's Next...

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Above 50 Day Moving Average - Time to Sell...

Wedbush on Friday raised its price target on Artiva Biotherapeutics, Inc. (ARTV) to $23 from $18 while keeping an ‘Outperform’ rating on the shares.The new price target implies a potential upside of 730% to the stock’s closing price on Thursday. Shares of the company rallied 99% on Friday at the time of writing.The price target hike <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/16/3168298/0/en/artiva-biotherapeutics-announces-refractory-rheumatoid-arthritis-as-lead-indication-upcoming-data-releases-and-corporate-update.html">follows</a> the company’s announcement on Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its cell therapy candidate AlloNK for the treatment of refractory rheumatoid arthritis in combination with Rituximab. The company also said that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK.“Despite the many approved therapies in RA, there are over 100,000 patients in the United States who remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy,” CEO Fred Aslan explained.Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects over 1.5 million people in the United States and can cause painful joint inflammation, progressive joint damage, and disability. A significant subset becomes refractory and no longer responds to or tolerates available treatment options.The company now plans to share safety and translational data for AlloNK in mid-November from patients treated with AlloNK and Rituximab across multiple autoimmune diseases, followed by clinical response data in the first half of 2026 from over 15 refractory RA patients. The CEO also added that the company is planning interactions with the FDA in the first half of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARTV">ARTV stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:588/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_10_20_08_AM_png_e279bf0c53.webp" alt="ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="588" height="62"><figcaption>ARTV's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally further.<stembedurl>https://stocktwits.com/bzspy/message/632725500</stembedurl>ARTV stock is down by 45% this year and by 57% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-supervised-autonomy-analyst-warns-ahead-q3-earnings-valuation-177x-pe/ch6rM5XR3Fe">Tesla Still In ‘Supervised Autonomy,’ Says Analyst As Q3 Earnings Day Nears: ‘Shouldn’t Trade At 177x P/E’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Shares of PepGen (PEPG) more than doubled on Thursday morning after multiple analysts raised their price targets on the stock following the release of positive clinical data from an early-stage study in patients with myotonic dystrophy type 1.Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.Myotonic dystrophy type 1 (DM1) is a progressive disorder that primarily affects skeletal, cardiac, and smooth muscle. It is estimated to affect about 40,000 patients in the U.S.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-highest-mean-splicing-correction-reported-dm1">announced</a> on Wednesday that a 53.7% mean splicing correction was observed in DM1 patients following a single 15 mg/kg dose of its PGN-EDODM1, which is higher than any previously reported splicing correction in DM1 patients. All patients who received the dose in the trial showed an improvement in splicing correction, the company noted.“Since mis-splicing is the underlying cause of DM1, we believe high levels of splicing correction have the potential to reverse the underlying molecular defects, and produce functional improvements in multiple outcome measures, including myotonia and muscle weakness, in repeat dose studies,” said Paul Streck, Executive Vice President of Research and Development at PepGen.The company previously reported mean splicing correction of 12.3% and 29.1%, respectively, with 5mg/kg and 10mg/kg doses of PGN-EDODM1.The investigational candidate was well-tolerated at a dose of 15 mg/kg, and no serious treatment-related adverse events were identified, the company stated. However, one patient had to receive oral antihistamines for treatment-related adverse events, it said.PepGen's nearly 54% correction sets a new benchmark and "strongly suggests that repeat dosing could yield clinically meaningful functional benefit," contends H.C. Wainwright.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PEPG">PEPG stock </a>rose from 'neutral' to 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels.&nbsp;PEPG stock is up 51% this year but down approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PepGen Stock More Than Doubles On Thursday – Check Out The New Price Targets On Wall Street

Wedbush raised its price target on PepGen to $9 from $7 and kept an ‘Outperform’ rating on the shares, while H.C. Wainwright hiked its price target on the stock to $12 from $8.

Shares of genetics research company 23andMe Holding Co, which recently filed for bankruptcy, notched its best session ever on Thursday after obtaining a legal nod to start an asset sale.Late on Wednesday, 23andMe said it had secured a U.S. bankruptcy court approval for its initial Chapter 11 motions, including wage payments, vendor compensation, and a $35-million debtor-in-possession financing agreement with JMB Capital Partners.&nbsp;The court also authorized a sale process for most of its assets, requiring buyers to adhere to 23andMe's consumer privacy policies.&nbsp;The company, working with Moelis, will solicit bids over 45 days. A second hearing on further relief, including final approval of the financing facility, is set for April 22.The news sent 23andMe's stock soaring more than 45% on Thursday, although it slid in after-hours trading.On Stocktwits, message volume about 23andMe has surged by over 26,000%, while its following has grown by 4% since the company filed for bankruptcy during the weekend.Sentiment on the platform shifted from 'bearish' to 'extremely bullish' in a day.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/ME_sentiment_and_message_volume_as_of_March_27_png_50af800a78.webp" alt="ME sentiment and message volume as of March 27.png" width="1318" height="302"><figcaption>ME sentiment and message volume as of March 27. | source: Stocktwits</figcaption></figure>Retail investors speculated on potential buyouts, including one from co-founder Anne Wojcicki, who stepped down as CEO after the bankruptcy filing to pursue a takeover as "an independent bidder."One user estimated the company's genetic data alone could be worth over $1 billion, suggesting a buyout in the "$3-$5 range”&nbsp;per share.They also argued that even at a lowball valuation of $10 per user, the company could still be worth $100 million after debt, making it an attractive acquisition target.<stembedurl>https://stocktwits.com/SWIMHOLE/message/609440102</stembedurl>Another saw a Wojcicki buyout as unlikely and speculated that Big Pharma, international buyers, or even Chinese biotech firm BGI could become potential acquirers.<stembedurl>https://stocktwits.com/Jack_du/message/609505055</stembedurl>Retail investors also cited a media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/british-investor-backs-rescue-of-failing-genetics-firm-23andme-swl58rsqs">report</a> about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort."We believe this business is not only salvageable but could be worth over a billion dollars if the right changes are made," he reportedly said.23andMe, founded in 2006 by Wojcicki, Linda Avey, and Paul Cusenza, quickly became one of the hottest biotech startups with its DNA testing services that let users explore their ancestry and genetic traits through simple "spit kits" mailed to their homes.The company went public via a blank-check merger in 2021, at the height of the COVID-19 pandemic, reaching a peak market capitalization of $6 billion.&nbsp;However, by 2024, its valuation had plummeted to just $120 million as it struggled to churn a profit despite amassing a customer base of 15 million.Following its bankruptcy filing, 23andMe's login portal crashed Monday evening as users rushed to delete their genetic data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view of 23andMe headquarters in Sunnyvale, California, United States on March 25, 2025. (Photo by Tayfun Coskun/Anadolu via Getty Images)

Lifeline For 23andMe? Stock Jumps After Court Greenlights Bankruptcy Asset Sale, Retail Weighs Possible Rescue Deals

Stocktwits users spotted a media report about Richard Magides, the director of Singapore-based Zentree Investment and 23andMe's second-largest shareholder, expressing interest in backing a rescue effort.

Tonix Pharmaceuticals saw its shares swing wildly between gains and losses on Wednesday morning as they started to trade following a 1-for-100 reverse stock split announced at the start of this week.&nbsp;The move aims to meet the Nasdaq's $1.00 minimum bid price requirement for continued listing.On Stocktwits, Tonix emerged as the most active biotech stock by message volume over the past 24 hours, but sentiment shifted from 'bullish' to 'neutral.'&nbsp;One popular post highlighted legal concerns, with the user accusing Tonix of manipulative practices such as "multiple RS [reverse stock splits] in a short time frame" and "lack of disclosures."A more optimistic user pointed to the Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, for FDA approval of Tonix's TNX-102 SL to treat fibromyalgia and the company's $10 million stock buyback announced in September as positive signs.<stembedurl>https://stocktwits.com/Camlandia/message/602920803</stembedurl><stembedurl>https://stocktwits.com/WARBUD/message/602912879</stembedurl>Tonix has reportedly executed multiple reverse stock splits in recent years, including in June 2024, May 2023, and May 2022, signaling a pattern of trying to maintain a minimum share price.&nbsp;The company's portfolio is focused on central nervous system disorders,&nbsp;prioritizing advancing TNX-102 SL.In December, the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">accepted</a> the New Drug Application (NDA) for TNX-102 SL for fibromyalgia, which is also under a separate study for acute stress reaction and acute stress disorder.Earlier in 2024, Tonix reaffirmed its commitment to developing a&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/tnxp-stocktwits-chatter-explodes-after-fda-nod-for-nda/cJaVYSzR1F">mpox</a> vaccine, signaling its diversified approach to product development.Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data.&nbsp;However, retail interest has also surged over the last three months, with Stocktwits message volume increasing by 1,750% and following jumping by nearly 10%.&nbsp;During that period, Tonix's stock price has gained more than 5%, although it has lost nearly 98% of its value over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tonix Pharma Dominates Retail Biotech Buzz After 1-for-100 Reverse Split, Sentiment Turns Neutral Amid Volatility 

Short interest in the stock has grown steadily since mid-December, rising from 0.9% to 8.5% by the end of January, according to Koyfin data. 

Shares of NRx Pharmaceuticals Inc. surged nearly 25% on Tuesday, its best session in&nbsp;almost three weeks, drawing heavy interest from retail traders.The surge followed news of a $27 million funding deal to fund the company’s planned purchase of Hope clinics.NRx’s Hope Therapeutics unit announced a stock purchase agreement with Smith &amp; Sauer, a private investment firm specializing in healthcare and technology investments.&nbsp;The agreement includes an immediate $2 million investment in NRx common stock and a $25 million purchase of Hope’s Series A preferred shares, with $6.75 million due by Feb. 7 and the remainder by April 1.&nbsp;The funds will be used to expand Interventional Psychiatry Clinics focused on treating severe depression and other psychological disorders.Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.&nbsp;He added that the company had initiated a financial advisory relationship to raise an additional $400 million for broader expansion.&nbsp;"Psychedelic Medications such as ketamine, neuromodulation technologies such as TMS, and digital therapeutics have sparked a revolution in psychiatry where for the first time patients with life threatening conditions such as depression and PTSD hope for a brighter future,” he said.Retail traders on Stocktwits took note, with message volume surging 94% on Tuesday and remaining at high levels ahead of Wednesday’s market open.&nbsp;Sentiment on the stock turned ‘bullish,’ with investors speculating on the impact of the projected $100 million revenue on earnings and share price.&nbsp;One user even predicted that the stock could more than double from current levels.<stembedurl>https://stocktwits.com/jonny80s/message/601877421</stembedurl><stembedurl>https://stocktwits.com/TheRealBomb/message/601781798</stembedurl>Despite losing 11% in value over the past year, NRx Pharmaceuticals has seen a 177% gain in the past three months, driven by increasing retail interest.&nbsp;The company’s follower count on Stocktwits has risen 3% over the last 12 months, while message volume has jumped 188%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding 

Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold. 

BIB
ProShares Ultra Nasdaq Biotechnology

Feed

News

Sentiment

Fundamentals

Info

Latest BIB News

BIBProShares Ultra Nasdaq Biotechnology